Comparative Pharmacology
Head-to-head clinical analysis: CRESTOR versus LOVASTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESTOR versus LOVASTATIN.
CRESTOR vs LOVASTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
Oral, 5-40 mg once daily. Initial dose typically 10-20 mg; max 40 mg.
10-80 mg orally once daily in the evening, starting at 10-20 mg once daily; maximum dose 80 mg/day.
None Documented
None Documented
The terminal elimination half-life is approximately 19 hours (range 13–20 hours). This long half-life allows once-daily dosing and provides sustained HMG-CoA reductase inhibition.
Clinical Note
moderateLovastatin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Norfloxacin
"The serum concentration of Norfloxacin can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Resveratrol
"The serum concentration of Resveratrol can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Betamethasone
Terminal elimination half-life: 1.5–2 hours for lovastatin acid; clinical context: short half-life supports evening dosing to maximize HMG-CoA reductase inhibition during peak cholesterol synthesis.
Approximately 90% of rosuvastatin is eliminated in feces (as unchanged drug and metabolites), and about 10% is excreted in urine (mainly as unchanged drug). Biliary excretion is the primary route for elimination of metabolites.
Renal: 10% (as metabolites); Fecal: 83% (primarily as metabolites); Biliary: minor; <5% excreted unchanged in urine.
Category C
Category D/X
Statin
Statin
"The serum concentration of Betamethasone can be increased when it is combined with Lovastatin."